CY1122692T1 - Ενωσεις τετραϋδροπυραζολοπυριμιδινης - Google Patents

Ενωσεις τετραϋδροπυραζολοπυριμιδινης

Info

Publication number
CY1122692T1
CY1122692T1 CY20181101275T CY181101275T CY1122692T1 CY 1122692 T1 CY1122692 T1 CY 1122692T1 CY 20181101275 T CY20181101275 T CY 20181101275T CY 181101275 T CY181101275 T CY 181101275T CY 1122692 T1 CY1122692 T1 CY 1122692T1
Authority
CY
Cyprus
Prior art keywords
tetrahydropyrazolopyrimidine
compounds
tetrahydropyrazolopyrimidine compounds
sle
toll
Prior art date
Application number
CY20181101275T
Other languages
English (en)
Inventor
Roch Boivin
Eric Carlson
Atsushi Endo
Hans Hansen
Sally Ishizaka
Matthew MACKEY
Sridhar NARAYAN
Takashi Satoh
Shawn Schiller
Lynn D. Hawkins
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of CY1122692T1 publication Critical patent/CY1122692T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Υλοποιήσεις της αποκάλυψης αφορούν ενώσεις τετραϋδροπυραζολοπυριμιδίνης που δρουν ως ανταγωνιστές ή αναστολείς για υποδοχείς τύπου-Toll 7 και/ή 8 και τη χρήση τους σε φαρμακευτικές συνθέσεις αποτελεσματικές για την αγωγή του συστηματικού ερυθηματώδους λύκου (SLE) και της νεφρίτιδας λύκου.
CY20181101275T 2012-05-31 2018-11-29 Ενωσεις τετραϋδροπυραζολοπυριμιδινης CY1122692T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261654023P 2012-05-31 2012-05-31
PCT/US2013/043679 WO2013181579A2 (en) 2012-05-31 2013-05-31 Tetrahydropyrazolopyrimidine compounds

Publications (1)

Publication Number Publication Date
CY1122692T1 true CY1122692T1 (el) 2020-07-31

Family

ID=48626649

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181101275T CY1122692T1 (el) 2012-05-31 2018-11-29 Ενωσεις τετραϋδροπυραζολοπυριμιδινης

Country Status (34)

Country Link
US (5) US9126999B2 (el)
EP (1) EP2855476B1 (el)
JP (2) JP6285918B2 (el)
KR (2) KR102268155B1 (el)
CN (2) CN107344941B (el)
AR (1) AR091236A1 (el)
AU (2) AU2013267204B8 (el)
BR (1) BR112014030060B1 (el)
CA (1) CA2874445C (el)
CL (1) CL2014003278A1 (el)
CY (1) CY1122692T1 (el)
DK (1) DK2855476T3 (el)
ES (1) ES2709119T3 (el)
HK (1) HK1203498A1 (el)
HR (1) HRP20181889T1 (el)
HU (1) HUE040562T2 (el)
IL (2) IL268013B2 (el)
JO (1) JO3407B1 (el)
LT (1) LT2855476T (el)
MX (1) MX368455B (el)
MY (1) MY172926A (el)
NZ (1) NZ703459A (el)
PE (2) PE20190973A1 (el)
PH (2) PH12014502660A1 (el)
PL (1) PL2855476T3 (el)
PT (1) PT2855476T (el)
RS (1) RS57977B1 (el)
RU (2) RU2677291C2 (el)
SG (1) SG11201407890VA (el)
SI (1) SI2855476T1 (el)
TW (1) TWI572606B (el)
UA (1) UA113440C2 (el)
WO (1) WO2013181579A2 (el)
ZA (1) ZA201409273B (el)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3407B1 (ar) * 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
AU2014334554B2 (en) 2013-10-14 2018-12-06 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
RU2671496C2 (ru) 2013-10-14 2018-11-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные 5-пиперидин-8-цианохинолина
US9643967B2 (en) 2013-12-13 2017-05-09 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors
EA031639B1 (ru) * 2014-03-27 2019-01-31 Янссен Фармацевтика Нв ЗАМЕЩЕННЫЕ 4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-а]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ И 2,3-ДИГИДРО-1H-ИМИДАЗО[1,2-b]ПИРАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ROS1
MX2017001462A (es) 2014-07-31 2017-05-23 Basf Se Proceso para la preparacion de pirazoles.
US9938100B2 (en) 2014-12-30 2018-04-10 Kodak Alaris Inc. System and method for metallic object detection in a media transport system
PE20180327A1 (es) 2015-05-11 2018-02-13 Basf Se Proceso para preparar 4-amino-piridazinas
WO2017004734A1 (zh) * 2015-07-03 2017-01-12 中国农业大学 苄基腙类化合物及其制备方法与应用
CN108699003B (zh) * 2016-02-02 2023-02-03 巴斯夫欧洲公司 制备吡唑类的催化氢化方法
CN107174585A (zh) * 2016-03-10 2017-09-19 兰州大学 可用作雄激素受体拮抗剂的吡啶并咪唑类化合物的新用途
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
AU2017307208B2 (en) 2016-07-30 2021-01-21 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors
WO2018024644A1 (en) * 2016-08-02 2018-02-08 Solvay Sa Manufacture of hydrazinyl compounds useful in the manufacture of pyrazole carboxylic acid and derivatives, hydrazinyl compounds and their use
EP3510024B1 (en) 2016-09-09 2021-11-17 Bristol-Myers Squibb Company Pyridyl substituted indole compounds
WO2018047081A1 (en) * 2016-09-09 2018-03-15 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors
CN110177793B (zh) * 2017-05-18 2021-12-21 江苏恒瑞医药股份有限公司 杂芳基并吡唑类衍生物、其制备方法及其在医药上的应用
WO2019028301A1 (en) 2017-08-04 2019-02-07 Bristol-Myers Squibb Company INDOLE COMPOUNDS SUBSTITUTED WITH [1,2,4] TRIAZOLO [4,3-A] PYRIDINYL
ES2909401T3 (es) 2017-08-04 2022-05-06 Bristol Myers Squibb Co Compuestos de indol sustituidos útiles como inhibidores de TLR7/8/9
WO2019099336A1 (en) 2017-11-14 2019-05-23 Bristol-Myers Squibb Company Substituted indole compounds
KR102037494B1 (ko) 2017-12-11 2019-10-28 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
SG11202005513TA (en) * 2017-12-15 2020-07-29 Bristol Myers Squibb Co Substituted indole ether compounds
US10544143B2 (en) 2017-12-18 2020-01-28 Bristol-Myers Squibb Company 4-azaindole compounds
SG11202005696YA (en) * 2017-12-19 2020-07-29 Bristol Myers Squibb Co Substituted indole compounds useful as tlr inhibitors
AU2018390543A1 (en) 2017-12-19 2020-08-06 Bristol-Myers Squibb Company 6-azaindole compounds
EA202091483A1 (ru) * 2017-12-19 2020-10-28 Бристол-Маерс Сквибб Компани Амидзамещенные индольные соединения, пригодные в качестве ингибиторов tlr
SG11202005733QA (en) * 2017-12-20 2020-07-29 Bristol Myers Squibb Co Diazaindole compounds
US11420958B2 (en) 2017-12-20 2022-08-23 Bristol-Myers Squibb Company Aryl and heteroaryl substituted indole compounds
SG11202005694RA (en) 2017-12-20 2020-07-29 Bristol Myers Squibb Co Amino indole compounds useful as tlr inhibitors
CN111432818A (zh) 2017-12-22 2020-07-17 诺华股份有限公司 用于治疗神经精神性***性红斑狼疮的吡唑并哌啶衍生物和吡唑并嘧啶衍生物
WO2019122164A1 (en) * 2017-12-22 2019-06-27 Solvay Sa Process for the manufacture of pyrazole carboxylic derivatives and precursors thereof
US20210238136A1 (en) * 2018-06-07 2021-08-05 Daiichi Sankyo Company, Limited Azetidine derivative, and prodrug thereof
WO2020048596A1 (en) * 2018-09-06 2020-03-12 F. Hoffmann-La Roche Ag Novel pyrazolopyridine compounds for the treatment of autoimmune disease
WO2020094749A1 (en) * 2018-11-09 2020-05-14 F. Hoffmann-La Roche Ag 5-[6-[[3-(4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl)azetidin-1-yl]methyl]morpholin-4-yl]quinoline-8-carbonitrile derivatives and similar compounds as tlr7-9 antagonists for treating systemic lupus erythematosus
AU2020218872A1 (en) * 2019-02-07 2021-08-26 Beigene, Ltd. Imidazo (2, 1-f) (1, 2, 4) triazin-4-amine derivatives as TLR7 agonist
EP4008720A4 (en) * 2019-08-02 2023-08-02 BeiGene, Ltd. IMIDAZO [2,1-F][1,2,4] TRIAZINE-4-AMINE DERIVATIVES AS A TLR8 AGONIST
KR20190120112A (ko) 2019-10-08 2019-10-23 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
US20230097700A1 (en) * 2019-12-06 2023-03-30 Daiichi Sankyo Company, Limited Azetidine sulfonamide compound
IL307203A (en) 2021-04-16 2023-11-01 Gilead Sciences Inc THIENOPYRROLE COMPOUNDS

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3116230B2 (ja) 1989-02-15 2000-12-11 武田薬品工業株式会社 三環式縮合ピリミジン誘導体
JPH04133055A (ja) 1990-09-25 1992-05-07 Konica Corp 色再現性の改良されたハロゲン化銀カラー写真感光材料
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
FR2733749B1 (fr) 1995-05-05 1997-06-13 Oreal Compositions pour la teinture des fibres keratiniques contenant des diamino pyrazoles, procede de teinture, nouveaux diamino pyrazoles et leur procede de preparation
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
US6472416B1 (en) 1999-08-27 2002-10-29 Abbott Laboratories Sulfonylphenylpyrazole compounds useful as COX-2 inhibitors
UA72611C2 (uk) 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
NZ526269A (en) 2000-12-06 2004-11-26 Aventis Pharma Gmbh Guanidine and amidine derivatives as factor Xa inhibitors having antithrombotic effect
SK11542003A3 (sk) * 2001-03-14 2004-07-07 Grnenthal Gmbh Substituované pyrazolopyrimidíny a tiazolopyrimidíny, spôsob ich výroby, liečivá tieto látky obsahujúce a ich použitie
JP2005527598A (ja) 2002-04-26 2005-09-15 ファイザー・プロダクツ・インク トリアリール−オキシ−アリール−スピロ−ピリミジン−２，４，６−トリオンメタロプロテイナーゼ阻害剤
DE10221100C1 (de) 2002-05-03 2003-06-05 Neuhaus Elektronik Gmbh Elektrisch leitfähige Dichtung sowie Verfahren und Vorrichtung zu deren Herstellung
JP2003327860A (ja) 2002-05-09 2003-11-19 Konica Minolta Holdings Inc 着色組成物、着色微粒子分散物、インクジェット用インク、インクジェット記録方法
DE60317684D1 (de) 2002-06-19 2008-01-03 Janssen Pharmaceutica Nv SUBSTITUIERTE 2,4-DIHYDROPYRROLOc3,4BÜCHINOLIN-9-ONDERIVATE, DIE SICH ALS PHOSPHODIESTERASEINHIBITOREN EIGNEN
JP4133055B2 (ja) 2002-07-11 2008-08-13 株式会社イトーキ 移載機構を備えた自動倉庫
ZA200500782B (en) * 2002-08-26 2007-10-31 Takeda Pharmaceutical Calcium receptor modulating compound and use thereof
ES2635838T3 (es) 2002-08-26 2017-10-05 Takeda Pharmaceutical Company Limited Compuesto modulador de receptores de calcio y su uso
AU2003274652A1 (en) 2002-10-23 2004-05-13 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
SE0300120D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
JP2006522744A (ja) * 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法
US20050009817A1 (en) 2003-04-30 2005-01-13 Jennifer Savoy Substituted heteroaryls
EP1628970A2 (en) 2003-04-30 2006-03-01 The Institutes of Pharmaceutical Discovery, LLC Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
AU2004248160B2 (en) 2003-06-12 2010-05-27 Merck Sharp & Dohme Corp. Prodrugs of mitotic kinesin inhibitors
US20060025337A1 (en) 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
AU2004253579B2 (en) 2003-07-01 2010-12-23 Biomol International L.P. Sirt1 modulators for manipulating cells/organism lifespan/stress response
US20050085531A1 (en) 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
FR2865208B1 (fr) 2004-01-16 2009-01-16 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique
US7279232B2 (en) 2004-01-26 2007-10-09 Universal Display Corporation Electroluminescent stability
US20080004263A1 (en) 2004-03-04 2008-01-03 Santora Vincent J Ligands of Follicle Stimulating Hormone Receptor and Methods of Use Thereof
BRPI0510639A (pt) 2004-05-04 2007-11-13 Acadia Pharm Inc composto ou um sal ou uma pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos de tratar ou prevenir distúrbios, de terapia de reposição hormonal, de abaixar nìveis de colesterol, triglicerìdeos ou ldl, de tratar cognição prejudicada ou prover neuroproteção, de prevenir concepção, de modular ou agonizar especificamente um ou mais receptores de estrogênio e, uso de um composto
US7825265B2 (en) 2004-05-04 2010-11-02 Acadia Pharmaceuticals Inc. Compounds with activity at estrogen receptors
SG156637A1 (en) 2004-10-12 2009-11-26 Decode Genetics Ehf Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease
US20060122222A1 (en) 2004-11-18 2006-06-08 The Institutes For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids
JPWO2006057448A1 (ja) 2004-11-26 2008-06-05 武田薬品工業株式会社 アリールアルカン酸誘導体
JP2008528510A (ja) 2005-01-20 2008-07-31 サートリス ファーマシューティカルズ， インコーポレイテッド 紅潮および／または薬物誘発性体重増加を処置するためのサーチュイン活性化化合物の使用
WO2006105440A2 (en) 2005-03-30 2006-10-05 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
WO2006129587A1 (ja) 2005-05-30 2006-12-07 Genecare Research Institute Co., Ltd. ピラゾロン誘導体を含有する医薬組成物
EP1905762A1 (en) 2005-05-30 2008-04-02 Genecare Research Institute Co., Ltd Pyrazolone derivative
WO2006133216A2 (en) 2005-06-06 2006-12-14 Smithkline Beecham Corporation 4-substituted arylamine derivatives and their use in pharmaceutical compositions
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
GB0513886D0 (en) 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
US20070149466A1 (en) 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
CA2620740A1 (en) 2005-09-01 2007-03-08 Astellas Pharma Inc. Pyridazinone derivatives used for the treatment of pain
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
EP1989205B1 (en) 2006-01-23 2012-06-13 Vertex Pharmceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
JPWO2007102531A1 (ja) 2006-03-08 2009-07-23 武田薬品工業株式会社 併用薬
JP2009534454A (ja) 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
CA2652816A1 (en) 2006-05-23 2007-12-06 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
CA2653005A1 (en) 2006-05-23 2007-12-06 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
EA200802417A1 (ru) 2006-06-09 2009-06-30 Икос Корпорейшн Замещенные фенилуксусные кислоты как dp-2-антагонисты
WO2008006583A1 (en) 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
MX2009000919A (es) 2006-08-04 2009-04-16 Merz Pharma Gmbh & Co Kgaa Pirazolopirimidinas substituidas, proceso para su preparacion y su uso como medicina.
WO2008033894A2 (en) 2006-09-14 2008-03-20 Acadia Pharmaceuticals Inc. Compounds with activity at estrogen receptors
EP2099454A4 (en) 2006-11-17 2010-11-10 Abbott Lab AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
JP2010518014A (ja) 2007-01-31 2010-05-27 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用な２−アミノピリジン誘導体
WO2008097538A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
EP2009002A1 (en) 2007-06-21 2008-12-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) New process for the manufacture of 1H-imidazo [4,5-c]-quinoline ring systems
EP2170337A4 (en) 2007-06-28 2013-12-18 Abbvie Inc NEW TRIAZOLOPYRIDAZINE
US8022209B2 (en) 2007-09-12 2011-09-20 Janssen Pharmaceutica Nv Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
CN101889014A (zh) 2007-11-15 2010-11-17 卫材R&D管理有限公司 富含对映体的咪唑并吖庚因酮化合物
JP2011506466A (ja) * 2007-12-11 2011-03-03 株式会社サイトパスファインダー カルボキサミド化合物ならびにケモカイン受容体アゴニストとしてのそれらの使用
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
PT2231642E (pt) 2008-01-11 2014-03-12 Novartis Ag Pirimidinas como inibidores de quinase
US20120010177A1 (en) 2008-02-20 2012-01-12 The Wistar Institute / North Carolina State University MicroRNA Modulators and Method for Identifying And Using The Same
US8338392B2 (en) 2008-02-20 2012-12-25 The Wistar Institute MicroRNA modulators and method for identifying and using the same
EP2259680A4 (en) 2008-03-04 2012-01-25 Merck Sharp & Dohme SOLUBLE EPOXYHYDROLASE INHIBITORS, COMPOSITIONS COMPRISING SUCH COMPOUNDS AND TREATMENT METHODS THEREWITH
WO2009148961A2 (en) 2008-05-29 2009-12-10 Wisconsin Alumni Research Foundation Drugs to prevent hpv infection
EP2300438A4 (en) 2008-06-11 2012-06-27 Merck Sharp & Dohme IMIDAZOLE DERIVATIVES AS FAAH INHIBITORS
EP2299824B1 (en) 2008-06-11 2013-06-19 Merck Sharp & Dohme Corp. Pyrazole derivatives useful as inhibitors of faah
US20110306597A1 (en) 2008-06-18 2011-12-15 James Michael Crawforth Nicotinamide Derivatives
EP2307377A1 (en) 2008-06-18 2011-04-13 Pfizer Limited Nicotinamide derivatives
WO2009158394A1 (en) 2008-06-25 2009-12-30 Bristol-Myers Squibb Company Diketo azolopiperidines and azolopiperazines as anti-hiv agents
US8263642B2 (en) 2008-06-25 2012-09-11 Vanderbilt University Antimicrobial compounds and methods of use thereof
JP5433691B2 (ja) 2008-06-25 2014-03-05 ブリストル−マイヤーズ スクイブ カンパニー Ｈｉｖ結合阻害剤としてのジケトピペリジン誘導体
TWI461423B (zh) 2008-07-02 2014-11-21 Astrazeneca Ab 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物
EP2326622A1 (en) 2008-07-28 2011-06-01 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
ES2463765T3 (es) 2008-08-04 2014-05-29 Merck Sharp & Dohme Corp. Derivados de oxazol útiles como inhibidores de la AHAG
US20110251172A1 (en) 2008-08-13 2011-10-13 Rivkin Alexey A Purine derivatives for treatment of alzheimer's disease
US8507491B2 (en) 2008-08-25 2013-08-13 Irm Llc Compounds and compositions as hedgehog pathway inhibitors
JP2012503623A (ja) 2008-09-24 2012-02-09 ビーエーエスエフ ソシエタス・ヨーロピア 無脊椎動物系害虫防除用ピラゾール化合物
WO2010096115A1 (en) * 2008-10-29 2010-08-26 Apath, Llc Compounds, compositions and methods for control of hepatitis c viral infections
JP2012508250A (ja) 2008-11-07 2012-04-05 ワイス・エルエルシー キノキサリン系のｌｘｒモジュレーター
WO2010083199A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
SG172800A1 (en) 2009-01-19 2011-08-29 Daiichi Sankyo Co Ltd Heteroatom-containing cyclic compound
LT2403499T (lt) 2009-03-02 2020-01-10 Stemsynergy Therapeutics, Inc. Būdai ir kompozicijos, skirti panaudoti vėžio gydymui ir wnt sąlygotų poveikių ląstelėje sumažinimui
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2010141696A1 (en) 2009-06-04 2010-12-09 Dara Biosciences, Inc. Methods of treating or preventing psoriasis, and/or alzheimer's disease using indane acetic acid derivatives
US20110021531A1 (en) 2009-07-27 2011-01-27 Chobanian Harry Oxazole derivatives useful as inhibitors of faah
US8669259B2 (en) 2009-08-26 2014-03-11 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
UY33001A (es) 2009-11-06 2011-05-31 Boehringer Ingelheim Int Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina
JP2013032290A (ja) * 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
WO2011072064A1 (en) 2009-12-08 2011-06-16 Array Biopharma Inc. S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors
FR2953837B1 (fr) 2009-12-10 2012-03-09 Sanofi Aventis Derives 9h-pyridino[3,4-b]indole disubstitues, leur preparation et leur utilisation therapeutique
WO2011079000A1 (en) 2009-12-22 2011-06-30 Schering Corporation DERIVATIVES OF 7,8-DIHYDRO-1H-IMIDAZO[2,1-b]PURIN-4(5H)-ONE AND METHODS OF USE THEREOF
JP2013517281A (ja) 2010-01-13 2013-05-16 テンペロ、ファーマシューティカルズ、インコーポレイテッド 化合物及び方法
BR112012018913A2 (pt) 2010-01-28 2017-06-20 Merck Sharp & Dohme "composição farmacêutica, e, uso da composição"
US20110190266A1 (en) 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
WO2011117381A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh B-raf kinase inhibitors
EP2552907B1 (en) 2010-03-26 2014-10-22 Boehringer Ingelheim International GmbH Pyridyltriazoles
EP2371219A1 (en) 2010-04-01 2011-10-05 Basf Se Herbicidal acylhydrazides
CA2795350C (en) 2010-04-05 2016-02-09 Mannkind Corporation Ire-1.alpha. inhibitors
JP5856606B2 (ja) 2010-04-22 2016-02-10 メルク・シャープ・エンド・ドーム・コーポレイション Ｆａａｈの調節薬として有用なオキサゾール誘導体
EP2560657B1 (en) 2010-04-23 2015-09-16 Kineta, Inc. Diarylpyridine anti-viral compounds
EP2401915A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
CN102048738A (zh) 2010-12-08 2011-05-11 辽宁利锋科技开发有限公司 含有环嘧耐平药用复合物的药物组合物制剂
KR102022716B1 (ko) 2011-07-29 2019-09-18 카리오팜 쎄라퓨틱스, 인코포레이티드 하이드라지드 함유 핵 수송 조절인자 및 이의 용도
BR112014001933A2 (pt) 2011-07-29 2017-02-21 Karyopharm Therapeutics Inc moduladores de transporte nuclear e usos dos mesmos
JP2013159564A (ja) * 2012-02-02 2013-08-19 Kowa Co ピラゾロピリミジン−７−アミン誘導体を有効成分とするｔｌｒ９阻害剤
HUE033704T2 (en) 2012-02-13 2017-12-28 Bristol Myers Squibb Co Enediyne Compounds, its conjugates and uses, and methods for doing so
AU2013270036B2 (en) 2012-05-31 2016-12-01 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR(gamma)
JO3407B1 (ar) * 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين

Also Published As

Publication number Publication date
EP2855476A2 (en) 2015-04-08
AR091236A1 (es) 2015-01-21
US20160339032A1 (en) 2016-11-24
US20130324547A1 (en) 2013-12-05
PL2855476T3 (pl) 2019-02-28
RU2018146532A3 (el) 2019-06-21
RU2014154397A (ru) 2016-07-27
BR112014030060A2 (pt) 2017-09-12
KR20210076210A (ko) 2021-06-23
UA113440C2 (xx) 2017-01-25
IL268013A (en) 2019-09-26
CA2874445C (en) 2022-06-21
ES2709119T3 (es) 2019-04-15
BR112014030060B1 (pt) 2022-05-31
IL235986B (en) 2019-11-28
KR102403007B1 (ko) 2022-05-31
TWI572606B (zh) 2017-03-01
JP2018087221A (ja) 2018-06-07
PH12014502660B1 (en) 2015-01-21
CN104507939B (zh) 2017-07-25
AU2013267204A1 (en) 2015-01-29
CN107344941A (zh) 2017-11-14
IL268013B1 (en) 2024-01-01
SI2855476T1 (sl) 2018-12-31
US9126999B2 (en) 2015-09-08
MX368455B (es) 2019-10-03
ZA201409273B (en) 2016-05-25
PH12014502660A1 (en) 2015-01-21
JP2015523981A (ja) 2015-08-20
JO3407B1 (ar) 2019-10-20
CA2874445A1 (en) 2013-12-05
PT2855476T (pt) 2018-12-03
US20200347050A1 (en) 2020-11-05
PH12019500522A1 (en) 2020-11-04
LT2855476T (lt) 2019-01-10
RU2677291C2 (ru) 2019-01-16
RU2018146532A (ru) 2019-01-31
DK2855476T3 (en) 2018-12-17
MY172926A (en) 2019-12-14
AU2013267204B8 (en) 2017-04-13
EP2855476B1 (en) 2018-09-05
NZ703459A (en) 2016-09-30
KR20150016366A (ko) 2015-02-11
US11130758B2 (en) 2021-09-28
US20180273532A1 (en) 2018-09-27
CN107344941B (zh) 2020-04-21
US9446046B2 (en) 2016-09-20
HRP20181889T1 (hr) 2019-01-11
IL268013B2 (en) 2024-05-01
US20160030430A1 (en) 2016-02-04
US9850242B2 (en) 2017-12-26
PE20190973A1 (es) 2019-07-09
TW201402575A (zh) 2014-01-16
KR102268155B1 (ko) 2021-06-24
RU2733959C2 (ru) 2020-10-08
AU2013267204A8 (en) 2017-04-13
AU2017204586A1 (en) 2017-07-27
MX2014014497A (es) 2015-06-02
PE20150220A1 (es) 2015-02-14
US10640500B2 (en) 2020-05-05
WO2013181579A2 (en) 2013-12-05
CN104507939A (zh) 2015-04-08
JP6619829B2 (ja) 2019-12-11
HUE040562T2 (hu) 2019-03-28
SG11201407890VA (en) 2014-12-30
JP6285918B2 (ja) 2018-02-28
CL2014003278A1 (es) 2015-06-12
HK1203498A1 (en) 2015-10-30
AU2017204586B2 (en) 2018-11-08
WO2013181579A3 (en) 2014-03-27
AU2013267204B2 (en) 2017-04-06
IL235986A0 (en) 2015-02-01
RS57977B1 (sr) 2019-01-31

Similar Documents

Publication Publication Date Title
CY1122692T1 (el) Ενωσεις τετραϋδροπυραζολοπυριμιδινης
CY1122776T1 (el) Επιλεκτικως υποκατεστημενες ενωσεις κινολινης
CY1122718T1 (el) Σκευασμα συνδυασμου δυο αντι-ιικων ενωσεων
MX2016004629A (es) Compuestos de quinolina selectivamente sustituidos.
CL2016000925A1 (es) Inhibidores de bromodominio
CL2017000654A1 (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
CO2018000668A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
CO2017011151A2 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CY1119042T1 (el) Υποκατεστημενες ξανθινες και μεθοδοι χρησης αυτων
EA201591961A1 (ru) Ингибиторы акк и их применение
EA201591959A1 (ru) Ингибиторы акк и их применение
MY179781A (en) Biaryl inhibitors of bruton's tyrosine kinase
EA201591960A1 (ru) Ингибиторы акк и их применение
CL2016002169A1 (es) Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados.
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201592157A1 (ru) Низкомолекулярные ингибиторы фиброза
EA201591962A1 (ru) Ингибиторы акк и их применение
CY1122287T1 (el) Ενωσεις χρησιμες για την αναστολη toy ror-γαμμα-τ
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения
ES2523418R2 (es) Procedimiento de obtencion de composiciones protegidas para alimentacion animal, composiciones y uso de las mismas
EA201600032A1 (ru) Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина
ITUA20164278A1 (it) COMPOSTI 2-OXO-1,2-DIIDROPIRIDIN-3-CARBOSSAMMIDE E LORO USO COME INIBITORI DUALI DI PDK1/AurA
TH168487B (th) สารประกอบควิโนลีนที่ถูกแทนที่อย่างเลือกได้ (Selectively Substituted Quinoline Compounds)